Feed QDEL
QD

QuidelOrtho

QDEL · NASDAQ

$10.86 +1.02% (+$0.11)
1M -25.05%
Market Cap $740.6M
P/E Ratio -
Div. Yield -
ROE 55.30%

Bulios Fair Price

$6.76

37.8% downside

Current Price

$10.86

Undervalued Fair Value Overvalued

According to Bulios Fair Price, QDEL is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
3/9
Valuation
100 /100
Cheap
P/S 0.28x
P/B 0.42x
P/E N/A
Growth
0 /100
Declining
Rev. growth 5.80%
Book val. growth 26.99%
EPS growth N/A
Profitability
18 /100
Weak
Gross margin 44.60%
Net margin 39.20%
Op. margin 30.67%
Quality
6 /100
Poor
ROIC 16.34%
ROE 55.30%
ROA 18.34%
Debt
27 /100
High
Debt/Equity 1.73x
Current ratio 1.39x
Int. coverage -4.29x
Stability
56 /100
Moderate
Beta 0.68x
Rev. volatility 3.39%
EPS volatility 11,681.12%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about QDEL
Online

About the company

QuidelOrtho Corporation is a global biotechnology company specializing in diagnostics and rapid testing. Formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics, it has become a leader in diagnostic tests, focusing on infectious disease detection, immunoassays, and tests for chronic conditions. QuidelOrtho develops innovative diagnostic tools that accelerate diagnosis and improve healthcare, with products aimed at hospitals, laboratories, and home testing.

Sector

Healthcare

Industry

Medical - Specialties

CEO

Brian J. Blaser

Employees

6,500

Headquarters

San Diego

Upcoming events

04 NOV

Earnings

Upcoming earnings report

43d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.